Alumis Inc. has released a corporate presentation detailing recent advancements in its pipeline of precision-engineered TYK2 inhibitors for immune-mediated diseases. The company highlighted positive topline data from its Phase 3 ONWARD1 and ONWARD2 clinical trials, demonstrating that its lead candidate, envudeucitinib, achieved highly statistically significant efficacy in moderate-to-severe plaque psoriasis. The therapy showed rapid onset of action, deep skin clearance at 24 weeks, and improvements in quality of life and itch, with a safety profile consistent with prior studies. The presentation also outlined ongoing development of envudeucitinib for systemic lupus erythematosus and next-generation TYK2 inhibitor programs targeting neuroinflammation and other indications. Additional long-term psoriasis data and lupus trial results are expected in the second half of 2026. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alumis Inc. published the original content used to generate this news brief on January 12, 2026, and is solely responsible for the information contained therein.